Replies to post #35159 on Kiwa Bio-Tech Products Group Corp (fka KWBT)

[operating_line]

Exactly, agree with all.

100 million market cap could be realistic if financials next month confirms the expected sales. There was that earlier report suggesting 160 million.

https://seekingalpha.com/instablog/21922151-bioresearch-alert/5452232-two-cent-kwbt-ready-to-soar

Rong family were quite impressed at CAF 2018. Lets see if they follow through with anything. We had interest in Q2 from the a China state owned company via a first order of $7.5 million. This relationship can bear more fruit for KWBT so that is another possibility. Recent news of Bayer and Syngenta making acquisitions in the ag biotech space confirms the sector is heating up and these companies visit CAF.

Even if sales were to fall from expected 48 million to 30 million, PPS should reflect a market cap much higher than currently. If revenues can keep coming in to clean up the balance sheet, I hope they can show a solid agreement for discounting commercial notes with sufficient safety margin to avoid a squeeze again.

Lets hope Kiwa Biotech attends CAF again. Their HQ in Yangling is in well located for this.

[Cosm03]

Q1+Q2 sales were roughly around 40k tons. The goal for Q3 was 80K tons. As of September 30th, the Company completed three-fifths of the quarterly sales plan... So around 48K tons. 3 quarters, 88K tons. If they match the 48K tons in Q4, that would bring them to 136K tons for the year. Last year they did 162 and in 2018 they did 127k tons. The goal for this year was 200K tons. Just the facts. I made a post maybe a week ago that was negative on these figures, but they really are not all that bad considering the circumstances. If demand increases in Q4 like it did in 2018, I would not be surprised if they hit 140k+ tons for the year